| Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ... New England Journal of Medicine 369 (25), 2391-2405, 2013 | 2137 | 2013 |
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis C Harrison, JJ Kiladjian, HK Al-Ali, H Gisslinger, R Waltzman, ... New England Journal of Medicine 366 (9), 787-798, 2012 | 2020 | 2012 |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ... Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009 | 1529 | 2009 |
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis … A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007 | 1182 | 2007 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1083 | 2010 |
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ... Journal of clinical oncology 29 (6), 761, 2011 | 1035 | 2011 |
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ... New England Journal of Medicine 372 (5), 426-435, 2015 | 993 | 2015 |
| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 958 | 2013 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 874 | 2013 |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ... Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014 | 834 | 2014 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 820 | 2013 |
| Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (3), 840-846, 2007 | 637 | 2007 |
| The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion T Barbui, J Thiele, H Gisslinger, HM Kvasnicka, AM Vannucchi, ... Blood cancer journal 8 (2), 15, 2018 | 631 | 2018 |
| Effect of mutation order on myeloproliferative neoplasms CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ... New England Journal of Medicine 372 (7), 601-612, 2015 | 601 | 2015 |
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ... Journal of clinical oncology 29 (23), 3179-3184, 2011 | 588 | 2011 |
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for … G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ... Leukemia 22 (2), 437-438, 2008 | 558 | 2008 |
| Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet T Barbui, A Tefferi, AM Vannucchi, F Passamonti, RT Silver, R Hoffman, ... Leukemia 32 (5), 1057-1069, 2018 | 557 | 2018 |
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among … RM Emanuel, AC Dueck, HL Geyer, JJ Kiladjian, S Slot, S Zweegman, ... Journal of clinical oncology 30 (33), 4098-4103, 2012 | 525 | 2012 |
| Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia G Rotunno, C Mannarelli, P Guglielmelli, A Pacilli, A Pancrazzi, L Pieri, ... Blood, The Journal of the American Society of Hematology 123 (10), 1552-1555, 2014 | 520 | 2014 |
| Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, F Rodeghiero, ... Blood, The Journal of the American Society of Hematology 117 (22), 5857-5859, 2011 | 516 | 2011 |
